Organization (Academic)
Osaka University
ClinicalTrials.gov lists Osaka University as lead sponsor of 34 trials. It has 7 active development programs and 10 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo University of Osaka, via Wikimedia Commons, CC BY-SA 3.0. Shown to identify the organization; it may be a registered trademark.
This page covers Osaka University: 34 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (66)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Critical Illness | 3 |
| Dementia | 3 |
| Dyslipidemias | 3 |
| Meniere Disease | 3 |
| Alzheimer Disease | 2 |
Showing 5 of 66 disease areas.
Trials by start year as sponsor or collaborator (25)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 5 |
| 2019 | 5 |
| 2018 | 1 |
| 2017 | 1 |
Showing 10 of 25 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 37 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (7)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Radiation | Rectal Neoplasms | Phase 2 | 1 |
| Radiation | Colorectal Neoplasms | Phase 2 | 1 |
| AG chemotherapy | Rectal Neoplasms | Phase 2 | 1 |
| AG chemotherapy | Colorectal Neoplasms | Phase 2 | 1 |
| PSW-1025 | Prostatic Neoplasms | Phase 1 | 1 |
Showing 5 of 7 active programs.
Approved assets (10)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Dapagliflozin | 1 |
| isoniazed | 1 |
| Calcium (13C)Carbonate | 1 |
| Lansoprazole | 1 |
| Lanthanum Carbonate | 1 |
Showing 5 of 10 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 50% hit target (n=6) | 43% on time (n=7) |
Journals published in (42)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Annals of surgery | 3 |
| Journal of atherosclerosis and thrombosis | 3 |
| Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology | 2 |
| The British journal of surgery | 2 |
| Acta oto-laryngologica. Supplementum | 1 |
Showing 5 of 42 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 937 | 330 | 2025-12-23 |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Hiroshima University | Co sponsors trial with | 1 |
| Tokushima University | Co sponsors trial with | 1 |
| Nara Medical University | Co sponsors trial with | 1 |
| Kawasaki Medical School Hospital | Co sponsors trial with | 1 |
| Asakayama Hospital | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (981)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-23 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-09 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-11-25 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 981 events.
Biomarker capability evidence (44)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AR | Trial sponsor | Named in trial inclusion criteria |
| BCAR1 | Trial collaborator | Named in trial inclusion criteria |
| CSE1L | Trial collaborator | Named in trial inclusion criteria |
| CYP17A1 | Trial sponsor | Named in trial inclusion criteria |
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 44 evidence rows.
Biomarkers this organization publishes on (351)
Shown in this order: most publications first.
Showing 5 of 351 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.